Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

The stock's fall snapped a three-day winning streak.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

Gilead Sciences, Inc. (NASDAQ ... with some projecting it could become a $5 billion drug based on its profile. The company is preparing for approximately seven new treatment launches, focusing ...

Shares of Gilead Sciences Inc. GILD slid 2.04% to $96.04 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.95% to 6,025.99 ...